These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32526103)

  • 1. Major Congenital Malformation Risk After First Trimester Gestational Exposure to Oral or Intravenous Ondansetron.
    Andrade C
    J Clin Psychiatry; 2020 Jun; 81(3):. PubMed ID: 32526103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron for Treatment of Nausea and Vomiting of Pregnancy and the Risk of Specific Birth Defects.
    Parker SE; Van Bennekom C; Anderka M; Mitchell AA;
    Obstet Gynecol; 2018 Aug; 132(2):385-394. PubMed ID: 29995744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.
    Huybrechts KF; Hernández-Díaz S; Straub L; Gray KJ; Zhu Y; Patorno E; Desai RJ; Mogun H; Bateman BT
    JAMA; 2018 Dec; 320(23):2429-2437. PubMed ID: 30561479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Off-label use of ondansetron in pregnancy in Western Australia.
    Colvin L; Gill AW; Slack-Smith L; Stanley FJ; Bower C
    Biomed Res Int; 2013; 2013():909860. PubMed ID: 24396830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69).
    Nelson-Piercy C; Dean C; Shehmar M; Gadsby R; O'Hara M; Hodson K; Nana M;
    BJOG; 2024 Jun; 131(7):e1-e30. PubMed ID: 38311315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysis.
    Kaplan YC; Richardson JL; Keskin-Arslan E; Erol-Coskun H; Kennedy D
    Reprod Toxicol; 2019 Jun; 86():1-13. PubMed ID: 30849498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta-analysis.
    Picot C; Berard A; Grenet G; Ripoche E; Cucherat M; Cottin J
    Birth Defects Res; 2020 Aug; 112(13):996-1013. PubMed ID: 32420702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Pregnancy Outcomes of Patients Treated With Ondansetron vs Alternative Antiemetic Medications in a Multinational, Population-Based Cohort.
    Dormuth CR; Winquist B; Fisher A; Wu F; Reynier P; Suissa S; Dahl M; Ma Z; Lu X; Zhang J; Raymond CB; Filion KB; Platt RW; Moriello C; Paterson JM;
    JAMA Netw Open; 2021 Apr; 4(4):e215329. PubMed ID: 33890993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ondansetron and teratogenicity in rats: Evidence for a mechanism mediated via embryonic hERG blockade.
    Danielsson B; Webster WS; Ritchie HE
    Reprod Toxicol; 2018 Oct; 81():237-245. PubMed ID: 30149139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy outcome following in-utero exposure to ondansetron: A prospective comparative observational study.
    Sakran R; Shechtman S; Arnon J; Diav-Citrin O
    Reprod Toxicol; 2021 Jan; 99():9-14. PubMed ID: 33212170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States.
    Fejzo MS; MacGibbon KW; Mullin PM
    Reprod Toxicol; 2016 Jul; 62():87-91. PubMed ID: 27151373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New evidence for concern over the risk of birth defects from medications for nausea and vomitting of pregnancy.
    Bérard A; Sheehy O; Gorgui J; Zhao JP; Soares de Moura C; Bernatsky S
    J Clin Epidemiol; 2019 Dec; 116():39-48. PubMed ID: 31352006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.
    Huybrechts KF; Hernandez-Diaz S; Straub L; Gray KJ; Zhu Y; Mogun H; Bateman BT
    JAMA; 2020 Jan; 323(4):372-374. PubMed ID: 31730152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational Case Series Evaluation of the Granisetron Transdermal Patch System (Sancuso) for the Management of Nausea/Vomiting of Pregnancy.
    Le TN; Adler MT; Ouillette H; Berens P; Smith JA
    Am J Perinatol; 2017 Jul; 34(9):851-855. PubMed ID: 28231602
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of antiemetics for nausea and vomiting of pregnancy in an emergency department setting.
    Mayhall EA; Gray R; Lopes V; Matteson KA
    Am J Emerg Med; 2015 Jul; 33(7):882-6. PubMed ID: 25921968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First trimester ondansetron exposure and risk of structural birth defects.
    Zambelli-Weiner A; Via C; Yuen M; Weiner DJ; Kirby RS
    Reprod Toxicol; 2019 Jan; 83():14-20. PubMed ID: 30385129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ondansetron use in nausea and vomiting during pregnancy: A descriptive analysis of prescription patterns and patient characteristics in UK general practice.
    Slattery J; Quinten C; Candore G; Pinheiro L; Flynn R; Kurz X; Nordeng H
    Br J Clin Pharmacol; 2022 Oct; 88(10):4526-4539. PubMed ID: 35483963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of ondansetron during pregnancy and congenital malformations in the infant.
    Danielsson B; Wikner BN; Källén B
    Reprod Toxicol; 2014 Dec; 50():134-7. PubMed ID: 25450422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motherisk update. Is ondansetron safe for use during pregnancy?
    Koren G
    Can Fam Physician; 2012 Oct; 58(10):1092-3. PubMed ID: 23064917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran).
    Tincello DG; Johnstone MJ
    Postgrad Med J; 1996 Nov; 72(853):688-9. PubMed ID: 8944215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.